FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004455896> ?p ?o ?g. }

• W2004455896 endingPage "14" @default.
• W2004455896 startingPage "10" @default.
• W2004455896 abstract "The purpose of this study was to confirm the activity of interferon-alpha intraperitoneally in minimal residual epithelial ovarian cancer in a Phase II multi-institutional trial and to investigate the activity of the agent based on prior response to first-line platinum compounds.Ninety-two patients with minimal residual (<0.5 cm) epithelial ovarian cancer at reassessment laparotomy were entered into a multicenter trial of intraperitoneal interferon-alpha given for 12 cycles unless disease progression or unacceptable toxicity occurred first. Patients were considered favorable if they were platinum sensitive and/or relapsed 6 months or longer after completing treatment and unfavorable if they were platinum insensitive and/or relapsed shorter than 6 months after completing treatment and/or had stable or progressive disease during initial therapy. A third-look laparotomy was performed within 12 weeks of completion of treatment in those patients who were in clinical remission.Eighty patients were clinically evaluable for toxicity only (48 favorable, 32 unfavorable) and 46 of them were evaluable for response, of whom 25 were favorable (platinum sensitive) and 21 unfavorable (platinum resistant). In the favorable group, there was a 28% surgically documented response rate (7/25 patients): 16% (4/25) had complete responses (negative reassessment operation), 12% (3/25) had partial responses, 32% (8/25) were nonresponders, and 40% (10 patients) developed progressive disease before planned reassessment operation. In the unfavorable group, there were no responding patients: 6 were nonresponders at reassessment operation and 15 developed progressive disease before planned reassessment operation. Of the 80 patients evaluable for toxicity, the most common adverse effects that were more than grade 2 were gastrointestinal (12; 15%), fever (8; 10%), neutropenia (7;9%), and leukopenia (6; 8%). Grade 4 toxicity was seen in 5 patients; each had fever and gastrointestinal toxicity, and 1 each had neutropenia and thrombocytopenia.Interferon-alpha is an active and generally well-tolerated agent in favorable patients with minimal residual epithelial ovarian cancer at second-look surgery. These results are comparable to those achieved with cytotoxic chemotherapy. If Phase III trials are considered in the patients with minimal residual ovarian cancer, they should be limited to the platinum-sensitive patient population." @default.
• W2004455896 created "2016-06-24" @default.
• W2004455896 creator A5008367436 @default.
• W2004455896 creator A5012517342 @default.
• W2004455896 creator A5022476466 @default.
• W2004455896 creator A5031844208 @default.
• W2004455896 creator A5034099406 @default.
• W2004455896 creator A5061020526 @default.
• W2004455896 creator A5072505682 @default.
• W2004455896 date "1999-10-01" @default.
• W2004455896 modified "2023-09-26" @default.
• W2004455896 title "Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study" @default.
• W2004455896 cites W1967864609 @default.
• W2004455896 cites W1982270480 @default.
• W2004455896 cites W2004121163 @default.
• W2004455896 cites W2010954378 @default.
• W2004455896 cites W2084500050 @default.
• W2004455896 cites W2098863590 @default.
• W2004455896 cites W2111636750 @default.
• W2004455896 cites W2241933379 @default.
• W2004455896 cites W2316501478 @default.
• W2004455896 cites W2411633317 @default.
• W2004455896 doi "https://doi.org/10.1006/gyno.1999.5532" @default.
• W2004455896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10502418" @default.
• W2004455896 hasPublicationYear "1999" @default.
• W2004455896 type Work @default.
• W2004455896 sameAs 2004455896 @default.
• W2004455896 citedByCount "51" @default.
• W2004455896 countsByYear W20044558962012 @default.
• W2004455896 countsByYear W20044558962013 @default.
• W2004455896 countsByYear W20044558962014 @default.
• W2004455896 countsByYear W20044558962017 @default.
• W2004455896 countsByYear W20044558962018 @default.
• W2004455896 countsByYear W20044558962019 @default.
• W2004455896 countsByYear W20044558962022 @default.
• W2004455896 crossrefType "journal-article" @default.
• W2004455896 hasAuthorship W2004455896A5008367436 @default.
• W2004455896 hasAuthorship W2004455896A5012517342 @default.
• W2004455896 hasAuthorship W2004455896A5022476466 @default.
• W2004455896 hasAuthorship W2004455896A5031844208 @default.
• W2004455896 hasAuthorship W2004455896A5034099406 @default.
• W2004455896 hasAuthorship W2004455896A5061020526 @default.
• W2004455896 hasAuthorship W2004455896A5072505682 @default.
• W2004455896 hasConcept C121608353 @default.
• W2004455896 hasConcept C126322002 @default.
• W2004455896 hasConcept C141071460 @default.
• W2004455896 hasConcept C143998085 @default.
• W2004455896 hasConcept C203014093 @default.
• W2004455896 hasConcept C2776178377 @default.
• W2004455896 hasConcept C2776694085 @default.
• W2004455896 hasConcept C2777546739 @default.
• W2004455896 hasConcept C2777701055 @default.
• W2004455896 hasConcept C2778461978 @default.
• W2004455896 hasConcept C2778822529 @default.
• W2004455896 hasConcept C2779823535 @default.
• W2004455896 hasConcept C2780427987 @default.
• W2004455896 hasConcept C2780435969 @default.
• W2004455896 hasConcept C2780778865 @default.
• W2004455896 hasConcept C2781228144 @default.
• W2004455896 hasConcept C2909179924 @default.
• W2004455896 hasConcept C29730261 @default.
• W2004455896 hasConcept C3019054536 @default.
• W2004455896 hasConcept C31760486 @default.
• W2004455896 hasConcept C535046627 @default.
• W2004455896 hasConcept C71924100 @default.
• W2004455896 hasConcept C90924648 @default.
• W2004455896 hasConceptScore W2004455896C121608353 @default.
• W2004455896 hasConceptScore W2004455896C126322002 @default.
• W2004455896 hasConceptScore W2004455896C141071460 @default.
• W2004455896 hasConceptScore W2004455896C143998085 @default.
• W2004455896 hasConceptScore W2004455896C203014093 @default.
• W2004455896 hasConceptScore W2004455896C2776178377 @default.
• W2004455896 hasConceptScore W2004455896C2776694085 @default.
• W2004455896 hasConceptScore W2004455896C2777546739 @default.
• W2004455896 hasConceptScore W2004455896C2777701055 @default.
• W2004455896 hasConceptScore W2004455896C2778461978 @default.
• W2004455896 hasConceptScore W2004455896C2778822529 @default.
• W2004455896 hasConceptScore W2004455896C2779823535 @default.
• W2004455896 hasConceptScore W2004455896C2780427987 @default.
• W2004455896 hasConceptScore W2004455896C2780435969 @default.
• W2004455896 hasConceptScore W2004455896C2780778865 @default.
• W2004455896 hasConceptScore W2004455896C2781228144 @default.
• W2004455896 hasConceptScore W2004455896C2909179924 @default.
• W2004455896 hasConceptScore W2004455896C29730261 @default.
• W2004455896 hasConceptScore W2004455896C3019054536 @default.
• W2004455896 hasConceptScore W2004455896C31760486 @default.
• W2004455896 hasConceptScore W2004455896C535046627 @default.
• W2004455896 hasConceptScore W2004455896C71924100 @default.
• W2004455896 hasConceptScore W2004455896C90924648 @default.
• W2004455896 hasIssue "1" @default.
• W2004455896 hasLocation W20044558961 @default.
• W2004455896 hasLocation W20044558962 @default.
• W2004455896 hasOpenAccess W2004455896 @default.
• W2004455896 hasPrimaryLocation W20044558961 @default.
• W2004455896 hasRelatedWork W1972107383 @default.
• W2004455896 hasRelatedWork W1985882441 @default.
• W2004455896 hasRelatedWork W2004455896 @default.
• W2004455896 hasRelatedWork W2072767112 @default.

• next